MedKoo Cat#: 563550 | Name: Ro 90-7501
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ro 90-7501 is a potent promoter of both TLR3 and RLR ligand-induced IFN-β gene expression and antiviral response. It most likely acts via selective activation of p38 mitogen-activated protein kinase (MAPK) pathway.

Chemical Structure

Ro 90-7501
Ro 90-7501
CAS#293762-45-5

Theoretical Analysis

MedKoo Cat#: 563550

Name: Ro 90-7501

CAS#: 293762-45-5

Chemical Formula: C20H16N6

Exact Mass: 340.1436

Molecular Weight: 340.39

Elemental Analysis: C, 70.57; H, 4.74; N, 24.69

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
25mg USD 1,000.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RO 90-7501; RO 90 7501; RO 907501; RO907501; RO-90-7501;
IUPAC/Chemical Name
2'-(4-Aminophenyl)-[2,5'-bi-1H-benzimidazol]-5-amine
InChi Key
PAGZCEHLFCJSPV-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H16N6/c21-13-4-1-11(2-5-13)19-23-15-7-3-12(9-17(15)25-19)20-24-16-8-6-14(22)10-18(16)26-20/h1-10H,21-22H2,(H,23,25)(H,24,26)
SMILES Code
NC1=CC=C2C(N=C(C3=CC=C4C(N=C(C5=CC=C(N)C=C5)N4)=C3)N2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Biological target:
Ro 90-7501 is an inhibitor of amyloid β42 (Aβ42) fibril assembly. It reduces Aβ42-induced toxicity (EC50 = 2 μM).
In vitro activity:
Ro 90-7501 altered FRET, suggesting an increase in RyR2-CaM binding and a decrease DPc10 binding. Ro 90-7501 does not detrimentally affect myocyte Ca2+ transients. Ro 90-7501 partially inhibits overall Ca2+ leak, as assessed by Ca2+ sparks in permeabilized rat cardiomyocytes. Reference: J Mol Cell Cardiol. 2022 Jul;168:13-23. https://pubmed.ncbi.nlm.nih.gov/35405106/
In vivo activity:
To be determined
Solvent mg/mL mM
Solubility
DMSO 34.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 340.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Rebbeck R, Ginsburg KS, Ko CY, Fasoli A, Rusch K, Cai GF, Dong X, Thomas DD, Bers DM, Cornea RL. Synergistic FRET assays for drug discovery targeting RyR2 channels. J Mol Cell Cardiol. 2022 Jul;168:13-23. doi: 10.1016/j.yjmcc.2022.04.002. Epub 2022 Apr 9. PMID: 35405106; PMCID: PMC10088286. 2. Falci Finardi N, Kim H, Hernandez LZ, Russell MRG, Ho CM, Sreenu VB, Wenham HA, Merritt A, Strang BL. Identification and characterization of bisbenzimide compounds that inhibit human cytomegalovirus replication. J Gen Virol. 2021 Dec;102(12):001702. doi: 10.1099/jgv.0.001702. PMID: 34882533; PMCID: PMC8744270.
In vitro protocol:
1. Rebbeck R, Ginsburg KS, Ko CY, Fasoli A, Rusch K, Cai GF, Dong X, Thomas DD, Bers DM, Cornea RL. Synergistic FRET assays for drug discovery targeting RyR2 channels. J Mol Cell Cardiol. 2022 Jul;168:13-23. doi: 10.1016/j.yjmcc.2022.04.002. Epub 2022 Apr 9. PMID: 35405106; PMCID: PMC10088286. 2. Falci Finardi N, Kim H, Hernandez LZ, Russell MRG, Ho CM, Sreenu VB, Wenham HA, Merritt A, Strang BL. Identification and characterization of bisbenzimide compounds that inhibit human cytomegalovirus replication. J Gen Virol. 2021 Dec;102(12):001702. doi: 10.1099/jgv.0.001702. PMID: 34882533; PMCID: PMC8744270.
In vivo protocol:
To be determined
1: Tamari K, Sano K, Li Z, Seo Y, Otani K, Tatekawa S, Toratani M, Takaoka Y, Takahashi Y, Minami K, Isohashi F, Koizumi M, Ogawa K. Ro 90-7501 Is a Novel Radiosensitizer for Cervical Cancer Cells that Inhibits ATM Phosphorylation. Anticancer Res. 2019 Sep;39(9):4805-4810. doi: 10.21873/anticanres.13665. PMID: 31519582. 2: Hong TJ, Park K, Choi EW, Hahn JS. Ro 90-7501 inhibits PP5 through a novel, TPR-dependent mechanism. Biochem Biophys Res Commun. 2017 Jan 8;482(2):215-220. doi: 10.1016/j.bbrc.2016.11.043. Epub 2016 Nov 10. PMID: 27840051. 3: Guo F, Mead J, Aliya N, Wang L, Cuconati A, Wei L, Li K, Block TM, Guo JT, Chang J. RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response. PLoS One. 2012;7(10):e42583. doi: 10.1371/journal.pone.0042583. Epub 2012 Oct 3. PMID: 23056170; PMCID: PMC3463586. 4: Falci Finardi N, Kim H, Hernandez LZ, Russell MRG, Ho CM, Sreenu VB, Wenham HA, Merritt A, Strang BL. Identification and characterization of bisbenzimide compounds that inhibit human cytomegalovirus replication. J Gen Virol. 2021 Dec;102(12):001702. doi: 10.1099/jgv.0.001702. PMID: 34882533; PMCID: PMC8744270. 5: Rebbeck R, Ginsburg KS, Ko CY, Fasoli A, Rusch K, Cai GF, Dong X, Thomas DD, Bers DM, Cornea RL. Synergistic FRET assays for drug discovery targeting RyR2 channels. J Mol Cell Cardiol. 2022 Jul;168:13-23. doi: 10.1016/j.yjmcc.2022.04.002. Epub 2022 Apr 9. PMID: 35405106; PMCID: PMC10088286. 6: Li X, Li X, Wang H, Zhao X. Exploring hub pyroptosis-related genes, molecular subtypes, and potential drugs in ankylosing spondylitis by comprehensive bioinformatics analysis and molecular docking. BMC Musculoskelet Disord. 2023 Jun 29;24(1):532. doi: 10.1186/s12891-023-06664-8. PMID: 37386410; PMCID: PMC10308648. 7: Zhou F, Liu Y, Liu D, Xie Y, Zhou X. Identification of basement membrane- related signatures for estimating prognosis, immune infiltration landscape and drug candidates in pancreatic adenocarcinoma. J Cancer. 2024 Jan 1;15(2):401-417. doi: 10.7150/jca.89665. PMID: 38169540; PMCID: PMC10758037. 8: Alakwaa FM. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data. mSystems. 2020 Apr 14;5(2):e00297-20. doi: 10.1128/mSystems.00297-20. PMID: 32291351; PMCID: PMC7159901. 9: Zulauf KE, Kirby JE. Discovery of small-molecule inhibitors of multidrug- resistance plasmid maintenance using a high-throughput screening approach. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29839-29850. doi: 10.1073/pnas.2005948117. Epub 2020 Nov 9. PMID: 33168749; PMCID: PMC7703651. 10: Ma D, Yang Y, Cai Q, Ye F, Deng X, Shen B. Identification of a lncRNA based signature for pancreatic cancer survival to predict immune landscape and potential therapeutic drugs. Front Genet. 2022 Sep 14;13:973444. doi: 10.3389/fgene.2022.973444. PMID: 36186449; PMCID: PMC9515791. 11: Sun Q, Li YJ, Ning SB. Investigating the molecular mechanisms underlying the co-occurrence of Parkinson's disease and inflammatory bowel disease through the integration of multiple datasets. Sci Rep. 2024 Jul 24;14(1):17028. doi: 10.1038/s41598-024-67890-1. PMID: 39043798; PMCID: PMC11266657. 12: Bohrmann B, Adrian M, Dubochet J, Kuner P, Müller F, Huber W, Nordstedt C, Döbeli H. Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J Struct Biol. 2000 Jun;130(2-3):232-46. doi: 10.1006/jsbi.2000.4241. PMID: 10940228.